0001209191-19-001912.txt : 20190104
0001209191-19-001912.hdr.sgml : 20190104
20190104161743
ACCESSION NUMBER: 0001209191-19-001912
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190102
FILED AS OF DATE: 20190104
DATE AS OF CHANGE: 20190104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Davidson David
CENTRAL INDEX KEY: 0001578696
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35966
FILM NUMBER: 19510285
MAIL ADDRESS:
STREET 1: C/O BLUEBIRD BIO, INC.
STREET 2: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: bluebird bio, Inc.
CENTRAL INDEX KEY: 0001293971
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 60 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 339-499-9300
MAIL ADDRESS:
STREET 1: 60 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc
DATE OF NAME CHANGE: 20040616
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-01-02
0
0001293971
bluebird bio, Inc.
BLUE
0001578696
Davidson David
C/O BLUEBIRD BIO, INC.
60 BINNEY STREET
CAMBRIDGE
MA
02142
0
1
0
0
Chief Medical Officer
Common Stock
2019-01-02
4
M
0
2800
5.5004
A
27705
D
Common Stock
2019-01-02
4
S
0
1600
96.3496
D
26105
D
Common Stock
2019-01-02
4
S
0
1200
97.0451
D
24905
D
Common Stock
2019-01-02
4
M
0
4700
24.47
A
29605
D
Common Stock
2019-01-02
4
S
0
4700
100.0881
D
24905
D
Common Stock
2019-01-03
4
M
0
100
24.47
A
25005
D
Common Stock
2019-01-03
4
S
0
100
100.32
D
24905
D
Stock Option (right to buy)
5.5004
2019-01-02
4
M
0
2800
0.00
D
2023-01-16
Common Stock
2800
16151
D
Stock Option (right to buy)
24.47
2019-01-02
4
M
0
4700
0.00
D
2024-03-03
Common Stock
4700
9300
D
Stock Option (right to buy)
24.47
2019-01-03
4
M
0
100
0.00
D
2024-03-03
Common Stock
100
9200
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 9, 2018.
The range in prices for the transaction reported on this line was $95.90 to $96.86. The average weighted price was $96.3496. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The range in prices for the transaction reported on this line was $96.90 to $97.60. The average weighted price was $97.0451. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The range in prices for the transaction reported on this line was $100.00 to $100.32. The average weighted price was $100.0881. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years.
This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter.
/s/ Jason F. Cole, Attorney-in-Fact
2019-01-04